



Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/001,934
				Filing Date	November 15, 2001
				First Named Inventor	Zoltan Nagy
				Art Unit	1643
				Examiner Name	K. A. Canella
Sheet	1	of	1	Attorney Docket Number	GPCG-P01-003

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,300,064	10-09-2001	Knappik et al.	
	AB	US-6,180,377	01-30-2001	Morgan et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	BG	WO-94/29451		12-22-1994	Celltech Ltd et al.		
	BH	WO-97/08320		03-06-1997	Morphosys Proteinoptimierung et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CJ	GE, <i>et al.</i> , "A Human Hybridoma Monoclonal Antibody (TrJ11) Recognizing a New HLA-DR Epitope Shared by DR4, DR8, DR11, and DRB1*1303," <i>Human Immunology</i> , 42:27-34 (1995).			
	CK	HANCOCK, <i>et al.</i> , " Production of Monoclonal Human Antibody to HLA-DR5(DRW11) by Mouse/Human Heterohybridomas," <i>Human Immunology</i> , 22:135-142 (1998).			
	CL	PISTILLO, <i>et al.</i> , "A Novel Approach to Human Anti-HLA mABs Production: Use of Phage Display Libraries," <i>Human Immunology</i> , 57:19-26 (1997).			
	CM	QUEEN, <i>et al.</i> , "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 86:10029-10033 (1989).			
	CN	VAUGHAN, <i>et al.</i> , "Human antibodies by design," <i>Nature Biotechnology</i> , 16:535-539 (1998).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	02/10/2009
-----------------------	---------------------------	--------------------	------------